Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e Antigen–negative patients receiving lamivudine therapy
dc.contributor.author | Lok, Anna Suk-Fong | en_US |
dc.contributor.author | Hussain, Munira T. | en_US |
dc.contributor.author | Cursano, Carmela | en_US |
dc.contributor.author | Margotti, Marzia | en_US |
dc.contributor.author | Gramenzi, Annagiulia | en_US |
dc.contributor.author | Luca Grazi, Gian | en_US |
dc.contributor.author | Jovine, Elio | en_US |
dc.contributor.author | Benardi, Mauro | en_US |
dc.contributor.author | Andreone, Pietro | en_US |
dc.date.accessioned | 2006-04-19T13:50:04Z | |
dc.date.available | 2006-04-19T13:50:04Z | |
dc.date.issued | 2000-11 | en_US |
dc.identifier.citation | Lok, Anna Suk-Fong; Hussain, Munira; Cursano, Carmela; Margotti, Marzia; Gramenzi, Annagiulia; Luca Grazi, Gian; Jovine, Elio; Benardi, Mauro; Andreone, Pietro (2000)."Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e Antigen–negative patients receiving lamivudine therapy." Hepatology 32(5): 1145-1153. <http://hdl.handle.net/2027.42/34780> | en_US |
dc.identifier.issn | 0270-9139 | en_US |
dc.identifier.issn | 1527-3350 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/34780 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=11050068&dopt=citation | en_US |
dc.description.abstract | Lamivudine has been shown to be effective in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B, but its long-term efficacy and the rate of resistant mutations in patients with HBeAg-negative chronic hepatitis B is less clear. Twenty-nine patients with HBeAg-negative chronic hepatitis B, who have received lamivudine for at least 1 year were studied to determine the antiviral response, the rate and pattern of lamivudine-resistant mutations, and the effect of lamivudine-resistant mutations on HBeAg status. The mean duration of treatment was 21 ± 7 months. Before treatment, core promoter variant was detected in 16 (55%) patients and precore stop codon variant in 18 (62%) patients. Serum hepatitis B virus (HBV) DNA was detected by solution hybridization assay in 62%, 4%, and 24% and by polymerase chain reaction (PCR) assay in 100%, 31%, and 40% at months 0, 6, and 24, respectively. The cumulative rates of detection of lamivudine-resistant mutations after 1 and 2 years of treatment were 10% and 56%, respectively. In addition to the duration of treatment, core promoter mutation was associated with the selection of lamivudine-resistant mutants. Three patients with lamivudine-resistant mutations had reversion of the precore stop codon mutation; in 2 patients this was accompanied by the reappearance of HBeAg. We found that lamivudine-resistant mutants were detected at similar rates in patients with HBeAg-negative as in patients with HBeAg-positive chronic hepatitis B. Additional changes in other parts of the HBV genome may restore the replication fitness of lamivudine-resistant mutants. | en_US |
dc.format.extent | 240962 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | W.B. Saunders | en_US |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Hepatology | en_US |
dc.title | Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e Antigen–negative patients receiving lamivudine therapy | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of Gastroenterology, University of Michigan and VA Medical Center, Ann Arbor, MI ; Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Box 0362, Ann Arbor, MI 48109. fax: 734-936-7392 | en_US |
dc.contributor.affiliationum | Division of Gastroenterology, University of Michigan and VA Medical Center, Ann Arbor, MI | en_US |
dc.contributor.affiliationother | Semiotica Medica, Dipartimento Di Medicina Interna, Cardioangiologia ed Epatologia, Universita di Bologna, Bologna, Italy | en_US |
dc.contributor.affiliationother | Semiotica Medica, Dipartimento Di Medicina Interna, Cardioangiologia ed Epatologia, Universita di Bologna, Bologna, Italy | en_US |
dc.contributor.affiliationother | Semiotica Medica, Dipartimento Di Medicina Interna, Cardioangiologia ed Epatologia, Universita di Bologna, Bologna, Italy | en_US |
dc.contributor.affiliationother | Dipartimento di Discipline Chirugiche, Rianimatorie e dei Trapianti, Universita di Bologna, Bologna, Italy | en_US |
dc.contributor.affiliationother | Dipartimento di Discipline Chirugiche, Rianimatorie e dei Trapianti, Universita di Bologna, Bologna, Italy | en_US |
dc.contributor.affiliationother | Semiotica Medica, Dipartimento Di Medicina Interna, Cardioangiologia ed Epatologia, Universita di Bologna, Bologna, Italy | en_US |
dc.contributor.affiliationother | Semiotica Medica, Dipartimento Di Medicina Interna, Cardioangiologia ed Epatologia, Universita di Bologna, Bologna, Italy | en_US |
dc.identifier.pmid | 11050068 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/34780/1/510320535_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1053/jhep.2000.19622 | en_US |
dc.identifier.source | Hepatology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.